NCT05630833 - A Study to Investigate the Efficacy and Safety With Gepotidacin in Japanese Female Participants With Uncomplicated Urinary Tract Infection (Acute Cystitis) | Biotech Hunter

Enrollment

380

Participants

Timeline

Start Date

January 11, 2023

Primary Completion Date

February 2, 2024

Study Completion Date

February 2, 2024

Conditions

Urinary Tract Infections

Interventions

DRUG

Gepotidacin

Gepotidacin will be administered.

DRUG

Nitrofurantoin

Nitrofurantoin will be administered.

DRUG

Placebo

Placebo will be administered.

Trial Locations (27)

263-0043

GSK Investigational Site, Chiba

270-0034

GSK Investigational Site, Chiba

272-0107

GSK Investigational Site, Chiba

286-0201

GSK Investigational Site, Chiba

810-0001

GSK Investigational Site, Fukuoka

811-0120

GSK Investigational Site, Fukuoka

814-0013

GSK Investigational Site, Fukuoka

816-0943

GSK Investigational Site, Fukuoka

370-0826

GSK Investigational Site, Gunma

006-0816

GSK Investigational Site, Hokkaido

300-0062

GSK Investigational Site, Ibaraki

305-0821

GSK Investigational Site, Ibaraki

890-0073

GSK Investigational Site, Kagoshima

231-0861

GSK Investigational Site, Kanagawa

232-0067

GSK Investigational Site, Kanagawa

781-0085

GSK Investigational Site, Kochi

980-0803

GSK Investigational Site, Miyagi

534-0024

GSK Investigational Site, Osaka

564-0063

GSK Investigational Site, Osaka

840-0831

GSK Investigational Site, Saga

352-0001

GSK Investigational Site, Saitama